GenEng News  Mar 21  Comment 
Scientists in the U.S. have demonstrated that long-term therapy with the selective estrogen receptor modulators (SERMs) tamoxifen and raloxifene helps to slow disease progression in a mouse model of one of the most common forms of muscular...
FiercePharma  Mar 20  Comment 
Incyte CEO Hervé Hoppenot scored a big pay raise in 2017, even after the FDA forced it and partner Eli Lilly to refile for approval of baricitinib, a highly anticipated rheumatoid arthritis drug that flubbed its first run at a green light.
Benzinga  Mar 14  Comment 
On CNBC's "Fast Money Final Trade", Dan Nathan said he would start buying Target Corporation (NYSE: TGT). Brian Kelly thinks Square Inc (NYSE: SQ) should be bought. Karen Finerman is a little bit nervous about the market and she wants to buy...
FiercePharma  Mar 7  Comment 
Eli Lilly and Boehringer Ingelheim are gunning for a heart-failure nod for diabetes drug Jardiance. And if they can get it, they want to be able to talk up the product’s effects on exercise ability, too.
FiercePharma  Mar 4  Comment 
Disconnects still exist in perceptions around migraines. Surveying both migraine sufferers and average consumers, Eli Lilly found significant understanding gaps between the two.
FiercePharma  Mar 2  Comment 
Since Eli Lilly CEO David Ricks took the helm last year, he’s shaken up management twice, launched new cost-cutting measures and instituted thousands of job cuts. And he collected a compensation package of nearly $16 million for his efforts.
FiercePharma  Feb 27  Comment 
Eli Lilly has some formidable competition coming in the GLP-1 diabetes class, so it’s wasting no time looking for growth avenues for its contender, Trulicity. And if new data are any indication, it may have just found one.
FiercePharma  Feb 27  Comment 
It’s been just five months since Eli Lilly breast cancer drug Verzenio hit the market, but the product has racked up its third approval, broadening its group of eligible patients and putting it on more even footing with rivals from Pfizer and...
FierceBiotech  Feb 20  Comment 
Eli Lilly has halted a phase 2 rheumatoid arthritis trial after getting a midstudy glimpse at the data. The setback leaves Lilly and partner Hanmi Pharmaceutical to weigh whether it is worth moving the Bruton's TKI forward in other indications.

Wikinvest © 2006, 2007, 2008, 2009, 2010, 2011, 2012. Use of this site is subject to express Terms of Service, Privacy Policy, and Disclaimer. By continuing past this page, you agree to abide by these terms. Any information provided by Wikinvest, including but not limited to company data, competitors, business analysis, market share, sales revenues and other operating metrics, earnings call analysis, conference call transcripts, industry information, or price targets should not be construed as research, trading tips or recommendations, or investment advice and is provided with no warrants as to its accuracy. Stock market data, including US and International equity symbols, stock quotes, share prices, earnings ratios, and other fundamental data is provided by data partners. Stock market quotes delayed at least 15 minutes for NASDAQ, 20 mins for NYSE and AMEX. Market data by Xignite. See data providers for more details. Company names, products, services and branding cited herein may be trademarks or registered trademarks of their respective owners. The use of trademarks or service marks of another is not a representation that the other is affiliated with, sponsors, is sponsored by, endorses, or is endorsed by Wikinvest.
Powered by MediaWiki